Company intelligence / Profile preview

Bright Biotech

Manchester, England, United Kingdombrightbiotech.co.uk ↗

Ownership: Private
Development stage: Preclinical

Overview

Bright Biotech has developed a proprietary platform using plant chloroplasts to produce high-quality recombinant proteins at scale. Their main commercial focus is supplying affordable growth factors and proteins to the cellular agriculture industry—especially for cultured meat—and to regenerative medicine sectors. The company claims ultra-scalable, sustainable production with reduced infrastructure costs compared to traditional bioreactors. No direct clinical results are reported as they do not develop therapeutic drugs themselves but enable others through their technology.

Therapeutic areas: Other
Modalities: Recombinant proteins (notably growth factors)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Bright Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Biotech.

Explore the full profile